Phaseline

Companies › Abion

Abion: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABN401 (vabametkib)
c-MET inhibitor
METPhase 2Advanced Solid TumorsFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05541822ABN401 (vabametkib)Phase 2Advanced Solid TumorsOncologyFeb 2029

Targets

MET (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Beijing Scitech-Mq Pharmaceuticals IDEAYA Biosciences Shanghai Henlius Biotech DeuterOncology

Companies built like this

Apollomics Beijing Pearl Biotechnology Limited Liability Company Beijing Scitech-Mq Pharmaceuticals NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.